Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
- Conditions
- Breast CancerLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative NeoplasmsNausea and VomitingNeuroblastomaOvarian CancerTesticular Germ Cell Tumor
- Interventions
- First Posted Date
- 2006-02-17
- Last Posted Date
- 2016-03-15
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT00293384
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders
- Conditions
- Chronic Myeloproliferative DisordersLeukemiaMyelodysplastic/Myeloproliferative Diseases
- First Posted Date
- 2006-02-17
- Last Posted Date
- 2010-05-06
- Lead Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Target Recruit Count
- 70
- Registration Number
- NCT00293410
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: pegfilgrastimBiological: rituximabDrug: cyclophosphamideDrug: doxorubicin hydrochlorideDrug: prednisoneDrug: vincristine sulfateOther: pharmacological studyRadiation: radiation therapy
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2021-05-18
- Lead Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
- Target Recruit Count
- 586
- Registration Number
- NCT00290667
- Locations
- 🇨🇿
University Hospital Brno, Brno, Czechia
🇫🇷Hopital Debrousse, Lyon, France
🇨🇿Charles University Hospital, Prague 5, Czechia
Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2020-09-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 55
- Registration Number
- NCT00290433
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer
- Conditions
- Chronic Myeloproliferative DisordersLeukemiaMyelodysplastic SyndromesLymphoma
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 68
- Registration Number
- NCT00290641
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
- Conditions
- Chronic Myeloproliferative DisordersDiamond-blackfan AnemiaFanconi AnemiaGraft Versus Host DiseaseLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 43
- Registration Number
- NCT00290628
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 67
- Registration Number
- NCT00290498
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Infants With Neuroblastoma
- Conditions
- Neuroblastoma
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Target Recruit Count
- 120
- Registration Number
- NCT00287950
- Locations
- 🇬🇧
Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom
🇬🇧Leicester Royal Infirmary, Leicester, England, United Kingdom
🇮🇪Our Lady's Hospital for Sick Children, Dublin, Ireland
Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 1500
- Registration Number
- NCT00288002
- Locations
- 🇩🇪
Universitaetsfrauenklinik Frankfurt, Neu-Isenburg, Germany
Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Drug: AdriblastinDrug: dexamethasoneDrug: ChlorambucilDrug: rituximabDrug: cyclophosphamideDrug: alkeranProcedure: Total body irradiation (8Gy/4fr)Drug: vincristine
- First Posted Date
- 2006-02-02
- Last Posted Date
- 2009-02-12
- Lead Sponsor
- French Innovative Leukemia Organisation
- Target Recruit Count
- 39
- Registration Number
- NCT00285389
- Locations
- 🇫🇷
Regional university hospital, Rennes, France
🇫🇷REgional Hospital, Tours, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.